Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

BACKGROUND: The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cho...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur Heart J
Главные авторы: Kühnast, Susan, van der Tuin, Sam J.L., van der Hoorn, José W.A., van Klinken, Jan B., Simic, Branko, Pieterman, Elsbet, Havekes, Louis M., Landmesser, Ulf, Lüscher, Thomas F., Willems van Dijk, Ko, Rensen, Patrick C.N., Jukema, J. Wouter, Princen, Hans M.G.
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2015
Предметы:
Basic Science
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4286319/
https://ncbi.nlm.nih.gov/pubmed/25142968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehu319
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы